Other O.R. Procedures of the Blood and Blood Forming Organs DRG Reimbursement

DRG 804 covers inpatient other operating room procedures of the blood and blood-forming organs without Complication or Comorbidity or Major Complication or Comorbidity, including spleen and bone marrow operations. It matters for inpatient reimbursement because it establishes the prospective payment grouping and base payment rate for routine-resource hematologic surgical admissions under Medicare.

DRG 804 Overview

DRG 804 encompasses inpatient cases involving other operating room procedures on the blood and blood-forming organs without a Complication or Comorbidity or Major Complication or Comorbidity. Typical clinical scenarios include diagnostic or therapeutic surgical procedures on the spleen, bone marrow interventions, and other hematologic operative treatments that do not meet CC or MCC criteria. This Diagnosis-Related Group matters for Medicare payment because it groups similar-resource inpatient stays for prospective payment and determines base reimbursement for hospitals treating these hematologic surgical cases. Accurate coding and documentation of procedures and comorbidities influence assignment to DRG 804 and the associated payment level.

Acute procedural optimization studies: randomized or prospective cohort studies that evaluate perioperative techniques, hemostatic strategies, or blood-conservation protocols used during operative procedures on the blood and blood-forming organs (for example, splenectomy variants, operative lymph node procedures, or vascular access-related surgeries). These studies enroll inpatients undergoing the index O.R. procedures and measure intraoperative blood loss, transfusion requirements, immediate complication rates, and length of stay to identify approaches that reduce acute morbidity. Findings are directly relevant to surgeons, anesthesiologists, and hospital finance teams because reductions in transfusions and complications can shorten admissions and lower costs within this DRG.
Comparative effectiveness and quality-of-care research: observational registry analyses or pragmatic trials comparing different perioperative pathways (enhanced recovery, standardized transfusion thresholds, or multimodal anticoagulation management) for patients with hematologic or vascular conditions who require operative interventions on the blood-forming organs. These studies typically include diverse inpatient populations—patients with anemia, coagulopathies, or myeloproliferative disorders—and assess outcomes such as readmission, postoperative bleeding, thrombotic events, and resource utilization. Results inform guideline development and payer policies by identifying care pathways that improve outcomes while containing costs for this DRG cohort.
Post-discharge outcomes and utilization studies: longitudinal cohort studies tracking medium- to long-term outcomes after discharge from an index admission for O.R. procedures of the blood and blood-forming organs, focusing on rehospitalization for bleeding or thrombotic complications, need for repeat interventions, patient-reported functional status, and downstream outpatient transfusion or hematology service use. These studies examine risk factors present at discharge (anticoagulation status, wound complications, comorbid immunosuppression) to stratify patients for targeted follow-up and transitional-care programs. Payers and discharge planners use this evidence to design post-acute care pathways and predict downstream costs tied to index DRG payments.

Acute procedural optimization studies: randomized or prospective cohort studies that evaluate perioperative techniques, hemostatic strategies, or blood-conservation protocols used during operative procedures on the blood and blood-forming organs (for example, splenectomy variants, operative lymph node procedures, or vascular access-related surgeries). These studies enroll inpatients undergoing the index O.R. procedures and measure intraoperative blood loss, transfusion requirements, immediate complication rates, and length of stay to identify approaches that reduce acute morbidity. Findings are directly relevant to surgeons, anesthesiologists, and hospital finance teams because reductions in transfusions and complications can shorten admissions and lower costs within this DRG.
Comparative effectiveness and quality-of-care research: observational registry analyses or pragmatic trials comparing different perioperative pathways (enhanced recovery, standardized transfusion thresholds, or multimodal anticoagulation management) for patients with hematologic or vascular conditions who require operative interventions on the blood-forming organs. These studies typically include diverse inpatient populations—patients with anemia, coagulopathies, or myeloproliferative disorders—and assess outcomes such as readmission, postoperative bleeding, thrombotic events, and resource utilization. Results inform guideline development and payer policies by identifying care pathways that improve outcomes while containing costs for this DRG cohort.
Post-discharge outcomes and utilization studies: longitudinal cohort studies tracking medium- to long-term outcomes after discharge from an index admission for O.R. procedures of the blood and blood-forming organs, focusing on rehospitalization for bleeding or thrombotic complications, need for repeat interventions, patient-reported functional status, and downstream outpatient transfusion or hematology service use. These studies examine risk factors present at discharge (anticoagulation status, wound complications, comorbid immunosuppression) to stratify patients for targeted follow-up and transitional-care programs. Payers and discharge planners use this evidence to design post-acute care pathways and predict downstream costs tied to index DRG payments.

OpenPayer

Summary & Overview

Other O.R. Procedures of the Blood and Blood Forming Organs without CC/MCC: Inpatient Reimbursement Overview

DRG 804 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes